Healthcare News

Dr. Charuworn’s extensive immunology drug development experience will help accelerate the clinical development of Coultreon’s first-in-class SIK3 inhibitor COL-5671 Leuven, Belgium. August 18, 2026....

Interim financial results, 9M 2025/261 October 2025 - 30 June 2026 Coloplast delivered Q3 organic growth of 6% and 5% EBIT growth1 in constant currencies. Strong quarter in both Chronic Care ex....

9M 2025/26Delårsrapport, 9M 2025/261. oktober 2025 – 30. juni 2026 Coloplast leverede i Q3 en organisk vækst på 6% og en EBIT-vækst1 på 5% i faste valutakurser. Stærkt kvartal i både Chronic Care ex....

Total revenue increases by 14% to CHF 119 millionOperating profit increases by 32% to CHF 32 million and net profit by 77% to CHF 28 millionFosmanogepix phase 3 program on track for data readout and...

14 % Wachstum des Gesamtumsatzes auf CHF 119 Mio.32 % Steigerung des Betriebsgewinns auf CHF 32 Mio. und 77 % Steigerung des Gewinns auf CHF 28 Mio.Phase-3-Programm mit Fosmanogepix auf Kurs für die...

– Entitles holders to receive net proceeds from sale of remaining Legacy Biosimilar Assets – – Completes transformation of Coherus Oncology into a fully integrated, innovative immuno-oncology company...

SAN DIEGO, Aug. 17, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that on August 14, 2026, the Compensation Committee of the Company’s Board of...

FOSTER CITY, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional...

Nominating and Governance Chair Carol Burt to become Lead Director.Ron Taylor to retire after more than 21 years of service on Resmed’s Board of Directors. SAN DIEGO, Aug. 17, 2026 (GLOBE NEWSWIRE)...

BRISBANE, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at...